Hence then, the article about janssen announces results from phase 3 maia study showing significant overall survival benefits for treatment with darzalex daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible )
Also on site :
- Woman accused of physically abusing five children at unlicensed daycare in Gates
- Olivia Wilde describes mortifying interaction with Tom Cruise after ‘f–ked up’ custody papers attack
- Several Israeli strikes hit southern Lebanon, state media reports